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Abstract
Objective: Given that the Women’s Health Initiative reported in 2002 increased risks of breast cancer and cardio-
vascular events with hormone therapy (HT) use and many women discontinued use, we assessed the use and perceived
efficacy of complementary and alternative medicines (CAMs) for menopausal symptom relief after discontinuation of HT.
Methods: Postmenopausal women aged 50 to 65 years within the United KingdomCollaborative Trial of Ovarian Cancer
Screeningwhowerewilling to take part in a secondary studyweremailed a survey to evaluatemenopausal symptommanagement.
Use and perceived efficacy of CAMs for relief of vasomotor symptoms (VMS) upon discontinuation of HT were examined.
Results: The survey was sent to 15,000 women between July 2 and July 9, 2008. Seventy-one percent (10,662 of
15,000) responded, and 10,607 women with complete data were included. Ever use of HT was reported by 60.2%
(6,383 of 10,607). At survey completion, 79.3% (5,060 of 6,383) had discontinued HT, with 89.7% (4,540 of 5,060)
of the latter reporting using one or more CAMs for VMS relief. About 70.4% (3,561 of 5,060) used herbal remedies,
with evening primrose oil (48.6%; 2,205 of 4,540) and black cohosh (30.3%;1,377 of 4,540) being most commonly
used. Exercise was used by 68.2% (3,098 of 4,540), whereas other behavioral/lifestyle approaches were less fre-
quently reported (13.9%; 629 of 4,540). Contrarily, more women (57%-72%) rated behavioral/lifestyle approaches
as effective compared with herbal remedies (28%-46%; rating Q4 on a Bhelpfulness[ scale from 1-10). Among medical
treatments, selective serotonin reuptake inhibitors were used by 10% and rated effective by 72.1%.
Conclusions: Although more women use over-the-counter medicines, behavioral/lifestyle approaches seem to
provide better relief of VMS. There is a pressing need for better evidence-based lay information to support decision-
making on CAM use for relief of VMS.
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W
omen may experience significant vasomotor, sex-
ual, psychological, and somatic symptoms during
the menopausal transition.1 Vasomotor symptoms
(VMS)Vhot flushes and night sweatsVare the most com-
mon,2 with one in two postmenopausal women reporting them
to be troublesome.3 A meta-analysis indicated that they often
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persist several years after menopause,4 compromising quality
of life and disrupting women’s sense of well-being.5
Hormone therapy (HT) is the most effective treatment of
VMS. It reduces frequency and severity by 75%6 and improves
health-related quality of life.7 However, HT use has been in
decline since 2002,8 when the Women’s Health Initiative
(WHI)9 reported increased risks of breast cancer and cardio-
vascular events in women using HT. This decline has been
associated with increasing use of complementary and alterna-
tive medicines (CAMs) for relief of menopausal symptoms.10
CAMs are a Bdiverse group of medical and health care systems,
practices and products that are not generally considered to be
part of conventional medicine.[11
Although the popularity of CAMs is high among women,
there is little evidence to support their use in the control of
menopausal symptoms. The efficacy data of herbal remedies
and phytoestrogens have so far been inconclusive. Only black
cohosh has been investigated systematically in randomized
trials, and a Cochrane review has concluded that there is in-
sufficient evidence to support its use.10,12 We report on the use
and perceived benefits of CAMs for relief of VMS in women
who discontinued HT after the WHI report, using a nested
cohort design within the United Kingdom Collaborative Trial
of Ovarian Cancer Screening (UKCTOCS).
METHODS
Study participants
The UKCTOCS is a randomized controlled trial (RCT)
assessing the impact of screening on ovarian cancer mortality.
Between April 2001 and October 2005, 202,638 apparently
healthy postmenopausal women aged 50 to 74 years were
recruited to the trial through 13 regional trial centers located in
NHS Trusts in England, Wales, and Northern Ireland and
randomized to annual screening with (1) serum CA125,
interpreted using the BRisk of Ovarian Cancer[ algorithm
(multimodal group, n = 50,640); (2) transvaginal ultrasound
(ultrasound group, n = 50,639); or (3) control (no screening, n =
101,359).13 Postmenopausal status in these women was de-
fined as more than 12 months of amenorrhea after natural
menopause or hysterectomy with ovarian conservation or more
than12months of HT commenced for menopausal symptoms.
The study was approved on May 30, 2006 by the Joint Uni-
versity College London/University College London Hospitals
Committees on the Ethics of Human Research (Committee A;
REC reference 06/Q0505/36).
Survey
At recruitment, all women completed a baseline datasheet
regarding reproductive and lifestyle factors and current HT
use. Three to 5 years after randomization, the women were
sent a postal follow-up questionnaire (FUQ). In addition to
lifestyle factors and medical history, the women were asked
about their current use of HT. Beginning July 2006, women
completing the FUQ were also asked whether they had used
any nonhormonal treatments to alleviate menopausal symp-
toms and if they would be willing to take part in a detailed
survey of how women deal with menopause. Women aged 50
to 65 years at FUQ completion who agreed to participate were
sent the Bmanaging menopausal symptoms[ (MMS) survey.
This included questions about any menopausal symptoms they
experienced and severity (rated as "bothersome" on a scale from
1 to 10) HT use (ever/current use), reasons for use (eg, hot
flushes, vaginal dryness, tiredness), and perceived helpfulness
for relief of hot flushes and night sweats. Those who had
discontinued HT were asked to select reasons for discontinua-
tion, to list any symptoms they had experienced since stopping
(eg, VMS), and if they had used any other therapies/treatments
for relieving VMS. The latter were broadly grouped into three
categories: (1) herbal/homeopathic remedies or over-the-
counter medicines (eg, black cohosh, evening primrose oil,
phytoestrogens); (2) behavioral/lifestyle approaches (eg, regular
exercise, yoga, counseling, and cognitive-behavioral therapy
[CBT]); or (3) other prescribed medical treatmentsVselective
serotonin reuptake inhibitors (SSRIs; eg, fluoxetine, paroxetine,
sertraline), serotonin-norepinephrine reuptake inhibitors (SNRIs;
eg, venlaflaxine), antihypertensive drugs (eg, clonidine), pro-
gestogens (eg, megestrol acetate), or antiepileptic drugs (eg,
gabapentin). For the purposes of this analysis, CAMs included
Bherbal/homeopathic remedies or over-the-counter medicines[
and Bbehavioral/lifestyle approaches,[ whereas Bmedical treat-
ments[ included all other prescribed treatments. As there have
been a number of studies examining the effects of exercise on
VMS relief,14,15 we included exercise in behavioral/lifestyle ap-
proaches that women may use for relief of menopausal symp-
toms even though it does not fall strictly under the definition of
BCAM.[ The women were asked to rate the level of helpfulness
with regard to relief of symptoms on a scale from 1 to 10 (1, Bno
effect[; 10, Bmost helpful[). For this analysis, treatments were
considered to be helpful in relieving VMS if they were rated 7
or higher (most effective) or 4 to 6 (moderately effective) on
the Bhelpfulness[ scale (1 to 3 on the scale was considered
minimally effective/ineffective).
Statistical analysis
Descriptive statistics were used to summarize the results
according to HT use, reasons for use of HT, reasons for stopping
HT, use of CAMs, and perceived helpfulness of CAMs.
RESULTS
Between July 2 and July 9, 2008, 15,000 UKCTOCS par-
ticipants aged 50 to 65 years who agreed to participate in the
MMS survey were sent the survey. Overall, 10,662 (71.1%)
returned the questionnaire. Fifty-five were excluded because
of errors in their study reference number (unique identifier). The
remaining 10,607 (70.7%) had complete data and were included
in the analysis. The baseline characteristics of responders and
nonresponders were very similar (Table 1, Supplemental Digi-
tal Content 1, http://links.lww.com/MENO/A111). The median
(interquartile range) age of women at completion of the MMS
survey was 59.8 (57.4-61.5) years. Women included in the
survey were postmenopausal, as defined in BMethods.[16
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Prevalence and severity of menopausal symptoms
When women were asked about symptoms they had expe-
rienced during the menopausal transition (Table 1), most
reported hot flushes (80.6%; 8,544 of 10,607) and night
sweats (72.5%; 7,690 of 10,607). Severe (Q7) symptoms were
reported by almost three quarters (73.5%; 7,795 of 10,607) of
women, with the most severe being night sweats (42.0%;
4,460 of 10,607), hot flushes (41.9%; 4,443 of 10,607), sleep
difficulties (37.6%; 3,987 of 10,607), and tiredness/fatigue
(29.2%; 3,094 of 10,607). Only 1.9% (197 of 10,607) of
women reported no symptoms at all.
HT use
Overall, 60.2% (6,383 of 10,607) of women reported ever
use of HT, of whom 12.3% (1,300 of 10,607) reported that
they were still using it at the time of completion of the MMS
survey. Of those reporting ever use of HT, 74.8% (4,776 of
6,383) took HT because they experienced hot flushes, night
sweats, and sleep difficulties (Table 2). Changes in mood
(40.1%; 2,557 of 6,383) and tiredness (37.3%; 2,380 of 6,383)
were the other reported indications. Although 41.7% (2,663 of
6,383) included prevention of osteoporosis as a reason for
having taken HT, only 3.0% (190 of 6,383) reported it as the
sole indication. Most women (71.8%; 4,585 of 6,383) used it
for multiple reasons. About 83.7% (5,342 of 6,383) of HT
users found it to be helpful.
In total, 79.3% (5,060 of 6,383) of HT ever users reported
that they had discontinued use. Specifically, 37.5% (2,396 of
6,383) of those younger than 60 years had discontinued use.
Over three-quarters (76.7%, 3,883 of 5,060) had discontinued
HT because of concerns regarding its safety: doctor’s advice,
45.2% (2,287 of 5,060); personal safety concerns, 38.9% (1,969
of 5,060); or media coverage of HT trials, 17.6% (891 of 5,060;
Table 3).
Upon discontinuation of HT, symptoms recurred in 93.1%
(4,712 of 5,060) of women, with more than two thirds (67.9%;
3,437 of 5,060) of women reporting severe (Q7) symptoms.
The most commonly reported symptoms continued to be hot
flushes (89.3%; 4,521 of 5,060), night sweats (79.5%; 4,025
of 5,060), and sleep difficulties (74.1%; 3,750 of 5,060; Table 4).
Of the women who discontinued HT, 70.2% were aware that
symptoms may recur.
CAMs for relief of VMS in women discontinuing HT
Overall, 42.8% (4,540 of 10,607) of women used CAMs. Of
those who had discontinued HT, 89.7% (4,540 of 5,060)
reported that they had used one or more CAMs. Use of indi-
vidual CAMs ranged widely (Fig.), with regular exercise being
most commonly used for relief of VMS (68.2%; 3,098 of
4,540; Table 5). Evening primrose oil was the only other option
used by half of the women (48.6%; 2,205 of 4,540). Herbal/
homeopathic remedies were used by 69.1% (3,495 of 5,060)
of the women. Black cohosh (30.3%; 1,377 of 4,540) and
phytoestrogens (25.0%; 1,137 of 4,540) were the other two
commonly used remedies. Although 72.7% (3,727 of 5,060)
used a behavioral/lifestyle approach, usage was low (13.9%;
629 of 4,540) if exercise was excluded. The other main ap-
proaches were diet alteration (24.9%; 1,129 of 4,540), meditation/
yoga (17.4%; 790 of 4,540), and relaxation/paced breathing
(17.4%; 790 of 4,540). Only 17.9% (813 of 4,540) used herbal/
TABLE 1. Prevalence of menopausal symptoms and severity
Symptom Women reporting symptomsa Women experiencing severe symptoms (rating 7-10)a
Hot flushes 8,544 (80.6) [79.8-81.3] 4,443 (41.9) [40.1-42.8]
Night sweats 7,690 (72.5) [71.6-73.3] 4,460 (42.0) [41.1-43.0]
Sleep difficulties 6,704 (63.2) [62.3-64.1] 3,987 (37.6) [36.7-38.5]
Vaginal dryness or pain during intercourse 5,104 (48.1) [47.2-49.1] 2,658 (25.1) [24.2-25.9]
Urinary problems 3,857 (36.4) [35.5-37.3] 1,765 (16.6) [15.9-17.4]
Tiredness or fatigue 6,605 (62.3) [61.4-63.2] 3,094 (29.2) [28.3-30.0]
Changes in mood 6,109 (57.6) [56.7-58.5] 2,867 (27.0) [26.2-27.9]
Low sex drive 6,040 (56.9) [56.0-57.9] 2,953 (27.8) [27.0-28.7]
Problems with memory 5,184 (48.9) [47.9-49.8] 1,770 (16.7) [16.0-17.4]
Other 952 (9.0) [8.4-9.5] 538 (5.1) [4.6-5.5]
Data are presented as n (%) [95% CI].
aAmong the overall cohort (N = 10,607).
TABLE 2. Reasons for taking/having taken hormone therapy
Reason Valuesa
Hot flushes/night sweats/sleep difficulties 4,776 (74.8) [73.7-75.9]
Prevent osteoporosis 2,663 (41.7) [40.5-42.9]
Changes in mood 2,557 (40.1) [38.8-41.3]
Tiredness or fatigue 2,380 (37.3) [36.1-38.5]
Vaginal dryness 1,217 (19.1) [18.1-20.0]
Problems with memory 1,188 (18.6) [17.7-19.6]
Low sex drive 831 (13.0) [12.2-13.9]
Feel/look younger 569 (8.9) [8.2-9.6]
Heart disease 356 (5.6) [5.0-6.2]
Other 763 (12.0) [11.2-12.8]
Data are presented as n (%) [95% CI].
aPercentage of hormone therapy users (n = 6,383).
TABLE 3. Reasons for stopping hormone therapy
Reason Valuesa
Doctor’s advice 2,287 (45.2) [43.8-46.6]
Concerns about safety of hormone therapy 1,969 (38.9) [37.6-40.3]
Age/duration 1,645 (32.5) [31.2-33.8]
Media (heard/read about the results of
hormone therapy trials)
891 (17.6) [16.6-18.7]
Adverse effects 644 (12.7) [11.8-13.7]
Another existing medical condition 493 (9.7) [8.9-10.6]
No benefit 474 (9.4) [8.6-10.2]
No longer experiencing symptoms 399 (7.9) [7.2-8.7]
Other 703 (13.9) [13.0-14.9]
Data are presented as n (%) [95% CI].
aPercentage of women who discontinued hormone therapy (n = 5,060).
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homeopathic remedies exclusively, and 23.0% (1,045 of 4,540)
used only behavioral/lifestyle approaches.
We further assessed whether patterns of CAM use differed
by age by subdividing the cohort into two groups: women
younger than the median age of 59.8 years and women older
than 59.8 years. Women who were older than 59.8 years at
survey completion reported higher use of all CAMs, except for
Menopace (Fig. 1, Supplemental Digital Content 2, http://
links.lww.com/MENO/A112).
Use of multiple CAM therapies
Overall, 58.6% of women used up to three CAM therapies,
with 22.0% (999 of 4,540) using one CAM therapy, 18.9%
(883 of 4,540) using two CAM therapies, and 58.5% (2,658 of
4,540) using three or more CAM therapies (Table 2, Supple-
mental Digital Content 1, http://links.lww.com/MENO/A111).
The latter included 39.0% (1,362 of 3,492) using three or more
herbal remedies and 29.5% (1,100 of 3,727) using three or
more lifestyle approaches.
Self-reported effectiveness
All behavioral/lifestyle approaches were rated to be effec-
tive by at least half of the women (rating Q4; Table 5), with
more than two thirds of those who had used mindfulness
(72.2%; 140 of 194), massage (71.1%; 521 of 733), medita-
tion/yoga (69.9%; 550 of 790), relaxation (68.8%; 544 of
791), regular exercise (70.6%; 2,186 of 3,098), or counseling
(67.1%; 153 of 228) reporting it to be effective in relieving
VMS. In contrast, all herbal/homeopathic remedies were rated
effective by less than half of the women who used them. Of
these, the highest ratings were for other herbal preparations
(46.3%; 312 of 674), phytoestrogens (45.6%; 519 of 1,137),
and vitamins (42.9%; 394 of 918). About 40.3% (889 of
2,205) of women using evening primrose oil and 29.6% (408 of
1,377) of women using black cohosh reported them to be useful.
Recommend use of CAMs to other women
Of those who used CAM remedies, few would recommend
their use to other women. The most recommended CAMs
were phytoestrogens (16.5%; 188 of 1,137) and evening
primrose oil (11.0%; 242 of 2,205), followed by black cohosh
(8.0%; 110 of 1,377; data not shown).
Medical treatments for relieving VMS in women
discontinuing HT
Women were also asked whether they had used any other
medical treatments (SSRIs, SNRIs, antihypertensive drugs,
progestogens, or antiepileptic drugs). Overall, 13.8% (697 of
TABLE 4. Symptoms reported by women stopping hormone therapy
Symptom Women reporting symptoms Women experiencing severe symptoms (7-10)a
Hot flushes 4,521 (89.3) [88.5-90.2] 2,382 (52.7) [51.2-54.2]
Night sweats 4,025 (79.5) [78.4-80.7] 2,241 (55.7) [54.1-57.2]
Sleep difficulties 3,750 (74.1) [72.9-75.3] 2,069 (55.2) [53.6-56.8]
Vaginal dryness 2,893 (57.2) [55.8-58.5] 1,472 (50.9) [49.0-52.7]
Urinary problems 2,148 (42.5) [41.1-43.8] 854 (39.8) [37.7-41.9]
Tiredness 3,357 (66.3) [65.0-67.7] 1,507 (44.9) [43.2-46.6]
Problems thinking 3,053 (60.3) [59.0-61.7] 1,046 (34.3) [32.6-36.0]
Changes in mood 2,766 (54.7) [53.3-56.0] 1,121 (40.5) [38.7-42.4]
Low sex drive 3,112 (61.5) [60.2-62.9] 1,508 (48.5) [46.7-50.2]
Other 437 (8.6) [7.9-9.4] 160 (36.6) [32.1-41.3]
Data are presented as n (%) [95% CI].
aAmong women who rated symptom severity.
FIG. Use and perceived efficacy of complementary and alternative medicine in menopausal symptom relief.
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5,060) of women used one or more medical treatments for
relief of VMS; SSRIs, in particular, were used by 10.3%
(523 of 5,060), of whom almost three quarters (72.1%; 377 of
523) found them helpful.
DISCUSSION
To our knowledge, this is, to date, the largest study of CAM
use in women who have discontinued HT. We are aware of
only one other study (based on data from 563 women) that
specifically explored CAM use in this population.17 Our
2008-2009 cross-sectional survey of more than 10,000 British
postmenopausal women aged 54 to 65 years showed that most
(93.1%) of the women who discontinued HT experienced re-
currence of symptoms, with three out of four women report-
ing severe (rating Q7) symptoms. About 89.7% used CAMs,
with most opting for herbal/homeopathic remedies. Impor-
tantly, although behavioral/lifestyle approaches, excluding
exercise, were used by only 13.9% of women, these were
reported to be more effective than herbal/homeopathic reme-
dies. More than two thirds of those who had used mindfulness,
massage, meditation/yoga, relaxation, and counseling repor-
ted them to be effective (score Q4), compared with less than
half of the women using herbal/homeopathic remedies. In
keeping with this, few women would recommend use of herbal/
homeopathic remedies to others for relief of menopausal symp-
toms. The data suggest a disconnect between women’s use
of herbal/lifestyle CAMs and women’s perceptions of their
effectiveness after having used them.
In our study, 60% of women reported ever use of HT, similar
to the 47.2% reported in the Million Women Study.18 Most
women had used it for multiple reasons, with hot flushes/night
sweats (74.8%) being the leading indication. Most (84%) found
TABLE 5. Use and perceived effectiveness of CAMs (herbal/homeopathic remedies and over-the-counter medicines or behavioral/lifestyle
approaches) or medical treatments in menopausal symptom relief by women who have stopped using hormone therapy
Therapy type
Women using
individual therapya Women rating 4-10 Women rating 7-10 Women rating 4-6 Women rating 1-3
Herbal/homeopathic remedies and over-the-counter medicines
Homeopathic
remedies
167 (3.7) [3.2-4.3] 54 (32.3) [25.3-40.0] 26 (15.6) [10.4-22.0] 28 (16.8) [11.4-23.3] 79 (47.3) [39.5-55.2]
Other herbal
preparations
674 (14.8) [13.8-15.9] 312 (46.3) [42.5-50.1] 132 (19.6) [16.6-22.8] 180 (26.7) [23.4-30.2] 300 (44.5) [40.7-48.4]
Phytoestrogens 1,137 (25.0) [23.8-26.3] 519 (45.6) [42.7-48.6] 170 (15.0) [12.9-17.2] 349 (30.7) [28.0-33.5] 564 (49.6) [46.7-52.6]
Vitamins 918 (20.2) [19.1-21.4] 394 (42.9) [39.7-46.2] 111 (12.1) [10.0-14.4] 283 (30.8) [27.9-33.9] 407 (44.3) [41.1-47.6]
Evening
primrose oil
2,205 (48.6) [47.1-50.0] 889 (40.3) [38.3-42.4] 242 (11.0) [9.7-12.4] 647 (29.3) [27.5-31.3] 1,131 (51.3) [49.2-53.4]
Ginseng 412 (9.1) [8.3-10.0] 163 (39.6) [34.8-44.5] 47 (11.4) [8.5-14.9] 116 (28.2) [23.9-32.8] 195 (47.3) [42.4-52.3]
Ginkgo 573 (12.6) [11.7-13.6] 223 (38.9) [34.9-43.1] 65 (11.3) [8.9-14.2] 158 (27.6) [24.0-31.4] 306 (53.4) [49.2-57.6]
Menopace 782 (17.2) [16.1-18.4] 293 (37.5) [34.1-41.0] 99 (12.7) [10.4-15.2] 194 (24.8) [21.8-28.0] 427 (54.6) [51.0-58.1]
Folk medicine
or traditional
Chinese
medicine
148 (3.3) [2.8-3.8] 54 (36.5) [28.7-44.8] 26 (17.6) [11.8-24.7] 28 (18.9) [13.0-26.2] 79 (53.4) [45.0-61.6]
Dong quai 322 (7.1) [6.4-7.9] 100 (31.1) [26.0-36.4] 33 (10.2) [7.2-14.1] 67 (20.8) [16.5-25.7] 205 (63.7) [58.2-68.9]
Black cohosh 1,377 (30.3) [29.0-31.7] 408 (29.6) [27.2-32.1] 134 (9.7) [8.2-11.4] 274 (19.9) [17.8-22.1] 910 (66.1) [63.6-68.6]
Kava kava 159 (3.5) [3.0-4.1] 44 (27.7) [20.9-35.3] 15 (9.4) [5.4-15.1] 29 (18.2) [12.6-25.1] 91 (57.2) [49.2-65.0]
Behavioral/lifestyle approaches
Mindfulness 194 (4.3) [3.7-4.9] 140 (72.2) [65.3-78.4] 63 (32.5) [25.9-40.0] 77 (39.7) [32.8-47.0] 37 (19.1) [13.8-25.3]
Massage 733 (16.1) [15.1-17.3] 521 (71.1) [67.7-74.3] 264 (36.0) [32.5-39.6] 257 (35.1) [31.6-38.6] 151 (20.6) [17.7-23.7]
Meditation
or yoga
790 (17.4) [16.3-18.5] 550 (69.9) [66.3-72.8] 240 (30.4) [27.2-33.7] 310 (39.2) [35.8-42.7] 171 (21.6) [18.8-24.7]
Relaxation/paced
breathing
791 (17.4) [16.3-18.6] 544 (68.8) [65.4-72.0] 216 (27.3) [24.2-30.6] 328 (41.5) [38.0-45.0] 179 (22.6) [19.8-25.7]
Regular exercise 3,098 (68.2) [66.9-69.6] 2,186 (70.6) [68.9-72.2] 1,102 (35.6) [33.9-37.3] 1,084 (35.0) [33.3-36.7] 517 (16.7) [15.4-18.1]
Counseling 228 (5.0) [4.4-5.7] 153 (67.1) [60.6-73.2] 87 (38.2) [31.8-44.8] 66 (28.9) [23.2-35.3] 53 (23.3) [17.9-29.3]
Altering usual diet 1,129 (24.9) [23.6-26.2] 717 (63.5) [60.6-66.3] 305 (27.0) [24.4-29.7] 412 (36.5) [33.7-39.4] 309 (27.4) [24.8-30.1]
Reflexology 510 (11.2) [10.3-12.2] 319 (62.5) [58.2-66.8] 144 (28.2) [24.4-32.4] 175 (34.3) [30.2-38.6] 146 (28.6) [24.7-32.8]
Cognitive-behavioral
therapy
127 (2.8) [2.3-3.3] 80 (63.0) [54.0-72.0] 45 (35.4) [27.2-44.4] 35 (27.6) [20.0-36.2] 28 (22.0) [15.2-30.3]
Stress
management
197 (4.3) [3.8-5.0] 117 (59.4) [52.2-66.3] 49 (24.9) [19.0-31.5] 68 (34.5) [27.9-41.6] 49 (24.9) [19.0-31.5]
Acupuncture or
acupressure
294 (6.5) [5.8-7.2] 167 (56.8) [51.0-62.5] 86 (29.3) [24.1-34.8] 84 (28.6) [23.5-34.1] 109 (37.1) [31.5-42.9]
Medical treatmentsb
SSRIs/SNRIs 523 (10.3) [9.5-11.2] 377 (72.1) [68.0-75.9] 244 (46.7) [42.3-51.0] 133 (25.4) [21.8-29.4] 94 (18.0) [14.8-21.5]
Antihypertensive
drugs
169 (3.3) [2.9-3.9] 70 (41.4) [33.9-49.2] 38 (22.5) [16.4-29.5] 32 (18.9) [13.3-25.7] 78 (46.2) [38.5-54.0]
Progestogens 43 (0.8) [0.6-1.1] 17 (39.5) [25.0-55.6] 8 (18.6) [8.4-33.4] 9 (20.9) [10.0-36.0] 22 (51.2) [35.5-66.7]
Antiepileptic drugs 68 (1.3) [1.0-1.7] 32 (47.1) [34.8-59.6] 20 (29.4) [19.0-41.2] 12 (17.6) [9.5-28.9] 27 (39.7) [28.0-52.3]
Data are presented as n (%) [95% CI].
CAM, complementary and alternative medicine; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor.
aAmong women who used individual therapy (among total CAM users, n = 4,540).
bAmong women who discontinued hormone therapy (n = 5,060).
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it helpful for relief of menopausal symptoms, but most (80%)
discontinued use, including 37% of women younger than
60 years. The main reasons were doctor’s advice, safety con-
cerns, and having heard/read about the results of HT trials.
Recently, a Norwegian study also reported on reasons for
stopping HT, with 30% of women discontinuing use because
of fear of adverse events,19 similar to the 39% of women in our
study reporting this as the main reason. Three out of four
women were aware that their symptoms would recur, and over
90% reported recurrence of symptoms upon discontinuing HT,
as also reported by the Norwegian study.19 Until June 2013,
guidelines on HT use had recommended that women use HT
for the shortest time possible. Despite guidelines now approv-
ing the use of HT for VMS up to age 60 years,20 the impact of
the original negative publicity is likely to be long-lasting.
The overall prevalence of CAM use in 2008-2009 (42.8%)
in this study is comparable to that (48%) reported on in a
meta-analysis in a recent systematic review of CAM sur-
veys.21 Small differences may be attributable to overrepre-
sentation of US women in the latter and inclusion of studies
before the publication of the WHI results in 2002.
Herbal medicine (black cohosh, donq quai, and evening
primrose), soy/phytoestrogens (including red clover), relaxa-
tion, and yoga were the most commonly used CAMs for
menopausal symptom relief in the recent systematic review.21
Half of the women surveyed reported use of herbal remedies,
with evening primrose oil (48.6%), black cohosh (30.3%), and
phytoestrogens (25.0%) being most commonly used. How-
ever, these were deemed effective (scores Q4) in relieving
symptoms by less than half of the women surveyed. Despite a
third of the women using black cohosh, more than two thirds
reported minimal effectiveness. Although many used herbal/
homeopathic remedies, few (phytoestrogens, 16.5%; evening
primrose oil, 11.0%; black cohosh, 8.0%) would recommend
these to other women.
Interestingly, nearly three quarters of the women reported
use of exercise as the approach of choice, with symptom relief
in 70%. The other lifestyle approaches, although used by
fewer women, were perceived as more effective than herbal
remedies. Interestingly, RCTs have not confirmed exercise to
be effective in alleviating VMS15,22 but have reported that it
may improve sleep and depression in postmenopausal women.14
Mindfulness has been shown to reduce distress and bother
from VMS compared with a wait-list control in an RCT.23
Furthermore, a recent prospective cohort study of 6,040 women
comparing two diet methods found Mediterranean-style diet
to be associated with fewer VMS.24 The treatments women
reported to be most effective (scores Q7) were counseling
(38%), massage (36%), and CBT (35%), consistent with pre-
vious findings suggesting that psychoeducational interventions
alleviate VMS.25 A recent RCT showed that CBT significantly
reduces problem ratings associated with VMS and the fre-
quency of night sweats26 and that CBT can be delivered with
little health professional time.27 Furthermore, CBT, whether
delivered in a group or in self-help format, is effective in re-
ducing the impact of VMS.28
In our study, few women used medical treatments other
than HT to relieve their VMS, with only 10% having used
SSRIs/SNRIs and with less than 5% having used antihyper-
tensive drugs, progestogen, or antiepileptic drugs. SSRIs have
consistently been reported, although with lower efficacy than
HT, to reduce the frequency and severity of VMS in RCTs.29<31
Seventy-two percent of women in our survey also reported
SSRIs to be effective, with almost half reporting them to be
very effective (scores Q7). Many women use CAMs to alleviate
menopausal symptoms, as there is a perception that CAMs are
safer and more Bnatural[ than HT. A recent review indicated
that 55% of women using CAMs did not disclose this to their
medical practitioner21 even though potentially life-threatening
adverse events, such as hepatitis and liver failure, have been
reported with use of black cohosh.32
Many women seek over-the-counter CAMs for menopausal
symptom relief. The discrepancy between women’s choice of
strategies, their perceptions of outcomes, and the current evi-
dence suggests that they would benefit from evidence-based
information about the efficacy of these interventions. An
earlier US survey of 413 women also suggested that women
do not feel sufficiently informed to make decisions regarding
CAM options for alleviating menopausal symptoms.33 A UK
National Institute for Health and Care Excellence guidance on
the effectiveness of menopausal treatments, which is sched-
uled to be published in 2015, is therefore most timely.
The main strengths of this study are its size, generalizability
(postmenopausal women from the general population across
England, Wales, and Northern Ireland), and the survey period
2008-2009, after the main WHI results9 but before data
reanalysis.34 We add to previous UK surveys that reported CAM
use between 2001 and 2006. As all women had previously used
HT, we believe that the efficacy of HT provided them a useful
reference for evaluating the effectiveness of CAMs in relieving
VMS. We also asked women which CAMs they would recom-
mend to other women, which we thought was a good indicator of
their overall experience with CAM use. Our study is in keeping
with most other studies that focused on relief of vasomotor
menopausal symptoms, which women find the most distressing.
There is currently a lack of evidence for management strategies
for menopausal symptoms in women who have discontinued
HT, and our study may provide useful guidance/information
regarding the use of alternative therapies for symptom relief. As
Espen Gjelsvik et al19 indicated, despite experiencing significant
VMS, women tend to prefer to live without HT, suggesting that
women are still concerned about the safety and adverse events
associated with HT use.
Limitations include the cross-sectional design of the study
and the possibility that the women who took part in the MMS
survey may have been more likely to have severe menopausal
symptoms and therefore more likely to try various treatment
modalities. In keeping with all previous surveys, there is in-
herent bias related to self-selection. There is a possibility of
recall bias. In addition, it is probable that women who had
troublesome (97) symptoms were more likely to have com-
pleted the survey. However, the prevalence of self-reported
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severe symptoms (73.5%) in our study is in keeping with
previous reports.35 Our questionnaire did not collect data on
exact formulation, dose, adverse events related to CAM use,
or concurrent use of multiple CAM treatments. The survey
included an exhaustive list of CAM therapies. There may be
newer therapies for VMS relief that women may have tried
since. The participants were mainly white; therefore, we are
unable to report on use among other ethnic groups. We did not
examine the relationship between HT/CAM use and variables
such as education, income, and smoking, which have previ-
ously been shown to influence a woman’s decision-making
regarding uptake of these therapies.
CONCLUSIONS
Although more women use over-the-counter medicines,
they report behavioral/lifestyle approaches to be more effec-
tive in alleviating VMS. This suggests the need for more
readily available evidence-based information to support
women’s decision-making.
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